BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 30, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Feb. 21, 2023

Feb. 21, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alterity, Apellis, Astellas, Chiesi, CSL, Iveric, Karyopharm, Menarini, Merck, Moderna, Specialised, Teva, Travere, Uniqure.
Read More

In the clinic for Feb. 21, 2023

Feb. 21, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amniotics, Jasper, Merck, Moderna, NS, Orion, Pfizer, Sarepta, Theriva, Valneva.
Read More
Infection

Novartis patents new 3CLpro inhibitors for SARS-CoV-2

Feb. 21, 2023
Novartis AG has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
Read More
Antibodies block virus from cell
Infection

Epitope-based identification of SARS-CoV-2-neutralizing antibodies from convalescent patients

Feb. 21, 2023
The emergence of new variants of concern (VOCs) of SARS-CoV-2 may limit the efficacy of monoclonal antibodies and vaccines currently used in the clinic.
Read More

Regulatory actions for Feb. 17, 2023

Feb. 17, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Axcella, Entera, Kancera, Nymox, Ose, Pharming, Redhill.
Read More

Shionogi advances oral COVID-19 antiviral ensitrelvir to phase III

Feb. 16, 2023
By Tamra Sami
After gaining emergency regulatory approval in Japan for its oral COVID-19 antiviral, 3CL protease inhibitor Xocova (ensitrelvir/S-217622), Shionogi & Co. Ltd. is advancing several global phase III trials across a wide range of COVID-19 patient populations. Branded as Xocova in Japan, ensitrelvir received emergency regulatory approval from Japan’s Ministry of Health, Labour and Welfare in late November 2022 for SARS-CoV-2 infection based on the results from phase II/III trials in non-hospitalized patients in Asia.
Read More

Regulatory actions for Feb. 15, 2023

Feb. 15, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Albireo, Athersys, Avidity, Biocon, Healios, Lemonex, Mirum, Neurona, Soligenix, Verve, Viatris.
Read More
Infection

Thylacine licenses exclusive rights to antiviral peptide platform developed at Columbia University

Feb. 15, 2023
Thylacine Biotherapeutics Inc. has entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform invented and refined at Columbia.
Read More

In the clinic for Feb. 14, 2023

Feb. 14, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Acumen, Akari, Alligator, BMS, Boan, Clene, Dermavant, Ena, Frequency, G1, Gensight, IMV, Luye, Moleculin, Ocular, Recbio, Regenxbio, Scancell, Seelos, Silver Creek, Skye.
Read More
Coronavirus and antibodies
Infection

Tonix exercises option to license anti-SARS-CoV-2 monoclonal antibodies from Columbia University

Feb. 14, 2023
Tonix Pharmaceuticals Holding Corp. has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.
Read More
Previous 1 2 … 51 52 53 54 55 56 57 58 59 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 30, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing